A Breakthrough in Interferon-based Therapies for Multiple Sclerosis

A Breakthrough in Interferon-based Therapies for Multiple Sclerosis

Source: 
BioSpace
snippet: 

- Heligenics, Inc., a pioneering biotechnology company applying functional genomics to drug discovery, announced today that it has reshaped the landscape of interferon beta drugs (IFN) which are widely-prescribed for Multiple Sclerosis.